Reactive oxygen species modulator 1 (Romo1) overexpression is an independent predictor of poor survival in NSCLC patients who undergo surgical resection

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: Reactive oxygen species modulator 1 (Romo1) is a novel protein that plays an important role in intracellular reactive oxygen species generation. Romo1 is overexpressed in most cancer cell lines and related to invasiveness and chemoresistance in vitro. However, little information is available on its clinical implications. We investigated the association between Romo1 expression and the clinical outcomes of non-small cell lung cancer (NSCLC) patients who underwent surgical resection. Materials and methods: Romo1 protein expressions were evaluated immunohistochemically in resected tumor specimens. Survival analyses for overall population (n = 110) and early-stage patients (n=97) were performed according to clinical parameters including level of Romo1 expression. Results: Multivariate analyses showed that high Romo1 expression in tumor tissues was significantly associated with short disease-free survival (hazard ratio [HR]=3.16, 95% confidence interval [CI]: 1.21-8.22), and with short overall survival (HR=3.22, 95% CI: 1.02-10.21). Stronger associations were observed between Romo1 expression and disease-free survival (HR=3.69, 95% CI: 1.39-9.97) and overall survival (HR=4.21, 95% CI: 1.12-14.67) in stage I and II patients than in the overall population. Romo1 expression was not associated with any clinical parameter including age, gender, smoking status, stage, differentiation, or tumor histology. Conclusions: Increased Romo1 expression in surgically resected NSCLC was found to be significantly associated with early recurrence and poor survival. Romo1 overexpression could be a potential adverse prognostic marker in this setting.

Original languageEnglish
Pages (from-to)45-52
Number of pages8
JournalLung Cancer
Volume87
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Non-Small Cell Lung Carcinoma
Reactive Oxygen Species
Survival
Confidence Intervals
Disease-Free Survival
Neoplasms
Survival Analysis
Population
Histology
Proteins
Multivariate Analysis
Smoking
Recurrence
Cell Line

Keywords

  • Biomarker
  • Non-small cell lung cancer
  • Oxidative stress
  • Prognosis
  • Reactive oxygen species
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

@article{ed66cf3fb1c34ded8751c93d7801fd65,
title = "Reactive oxygen species modulator 1 (Romo1) overexpression is an independent predictor of poor survival in NSCLC patients who undergo surgical resection",
abstract = "Objectives: Reactive oxygen species modulator 1 (Romo1) is a novel protein that plays an important role in intracellular reactive oxygen species generation. Romo1 is overexpressed in most cancer cell lines and related to invasiveness and chemoresistance in vitro. However, little information is available on its clinical implications. We investigated the association between Romo1 expression and the clinical outcomes of non-small cell lung cancer (NSCLC) patients who underwent surgical resection. Materials and methods: Romo1 protein expressions were evaluated immunohistochemically in resected tumor specimens. Survival analyses for overall population (n = 110) and early-stage patients (n=97) were performed according to clinical parameters including level of Romo1 expression. Results: Multivariate analyses showed that high Romo1 expression in tumor tissues was significantly associated with short disease-free survival (hazard ratio [HR]=3.16, 95{\%} confidence interval [CI]: 1.21-8.22), and with short overall survival (HR=3.22, 95{\%} CI: 1.02-10.21). Stronger associations were observed between Romo1 expression and disease-free survival (HR=3.69, 95{\%} CI: 1.39-9.97) and overall survival (HR=4.21, 95{\%} CI: 1.12-14.67) in stage I and II patients than in the overall population. Romo1 expression was not associated with any clinical parameter including age, gender, smoking status, stage, differentiation, or tumor histology. Conclusions: Increased Romo1 expression in surgically resected NSCLC was found to be significantly associated with early recurrence and poor survival. Romo1 overexpression could be a potential adverse prognostic marker in this setting.",
keywords = "Biomarker, Non-small cell lung cancer, Oxidative stress, Prognosis, Reactive oxygen species, Surgery",
author = "Lee, {Seung Hyeun} and Min, {Joo Won} and Lee, {Ji Sung} and Kim, {Chul Hwan} and Yoo, {Young Do} and Lee, {Eun Joo} and Kyung-Hoon Min and Hur, {Gyu Young} and Lee, {Seung Heon} and Lee, {Sung Yong} and Kim, {Je Hyeong} and Lee, {Sang Yeub} and Chol Shin and Shim, {Jae Jeong} and Kang, {Kyung Ho} and In, {Kwang Ho}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.lungcan.2014.11.004",
language = "English",
volume = "87",
pages = "45--52",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Reactive oxygen species modulator 1 (Romo1) overexpression is an independent predictor of poor survival in NSCLC patients who undergo surgical resection

AU - Lee, Seung Hyeun

AU - Min, Joo Won

AU - Lee, Ji Sung

AU - Kim, Chul Hwan

AU - Yoo, Young Do

AU - Lee, Eun Joo

AU - Min, Kyung-Hoon

AU - Hur, Gyu Young

AU - Lee, Seung Heon

AU - Lee, Sung Yong

AU - Kim, Je Hyeong

AU - Lee, Sang Yeub

AU - Shin, Chol

AU - Shim, Jae Jeong

AU - Kang, Kyung Ho

AU - In, Kwang Ho

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: Reactive oxygen species modulator 1 (Romo1) is a novel protein that plays an important role in intracellular reactive oxygen species generation. Romo1 is overexpressed in most cancer cell lines and related to invasiveness and chemoresistance in vitro. However, little information is available on its clinical implications. We investigated the association between Romo1 expression and the clinical outcomes of non-small cell lung cancer (NSCLC) patients who underwent surgical resection. Materials and methods: Romo1 protein expressions were evaluated immunohistochemically in resected tumor specimens. Survival analyses for overall population (n = 110) and early-stage patients (n=97) were performed according to clinical parameters including level of Romo1 expression. Results: Multivariate analyses showed that high Romo1 expression in tumor tissues was significantly associated with short disease-free survival (hazard ratio [HR]=3.16, 95% confidence interval [CI]: 1.21-8.22), and with short overall survival (HR=3.22, 95% CI: 1.02-10.21). Stronger associations were observed between Romo1 expression and disease-free survival (HR=3.69, 95% CI: 1.39-9.97) and overall survival (HR=4.21, 95% CI: 1.12-14.67) in stage I and II patients than in the overall population. Romo1 expression was not associated with any clinical parameter including age, gender, smoking status, stage, differentiation, or tumor histology. Conclusions: Increased Romo1 expression in surgically resected NSCLC was found to be significantly associated with early recurrence and poor survival. Romo1 overexpression could be a potential adverse prognostic marker in this setting.

AB - Objectives: Reactive oxygen species modulator 1 (Romo1) is a novel protein that plays an important role in intracellular reactive oxygen species generation. Romo1 is overexpressed in most cancer cell lines and related to invasiveness and chemoresistance in vitro. However, little information is available on its clinical implications. We investigated the association between Romo1 expression and the clinical outcomes of non-small cell lung cancer (NSCLC) patients who underwent surgical resection. Materials and methods: Romo1 protein expressions were evaluated immunohistochemically in resected tumor specimens. Survival analyses for overall population (n = 110) and early-stage patients (n=97) were performed according to clinical parameters including level of Romo1 expression. Results: Multivariate analyses showed that high Romo1 expression in tumor tissues was significantly associated with short disease-free survival (hazard ratio [HR]=3.16, 95% confidence interval [CI]: 1.21-8.22), and with short overall survival (HR=3.22, 95% CI: 1.02-10.21). Stronger associations were observed between Romo1 expression and disease-free survival (HR=3.69, 95% CI: 1.39-9.97) and overall survival (HR=4.21, 95% CI: 1.12-14.67) in stage I and II patients than in the overall population. Romo1 expression was not associated with any clinical parameter including age, gender, smoking status, stage, differentiation, or tumor histology. Conclusions: Increased Romo1 expression in surgically resected NSCLC was found to be significantly associated with early recurrence and poor survival. Romo1 overexpression could be a potential adverse prognostic marker in this setting.

KW - Biomarker

KW - Non-small cell lung cancer

KW - Oxidative stress

KW - Prognosis

KW - Reactive oxygen species

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84922240788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922240788&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2014.11.004

DO - 10.1016/j.lungcan.2014.11.004

M3 - Article

C2 - 25468147

AN - SCOPUS:84922240788

VL - 87

SP - 45

EP - 52

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -